Arquer Diagnostics Limited

The COVID-19 pandemic has created the need to manage cancer patients' backlog while reducing the unnecessary exposure of healthcare workers. For Symptomatic bladder cancer patients have not had the required tests to diagnose potential cancer, and patients who have previously had bladder cancer have been unable to undergo their t routine follow ups to chec...

This project will focus on the introduction of a novel technology to assist NHS in the stratification of urology patients (to ensure a quick diagnosis of patients at highest risk of having a bladder tumour). In the aftermath of COVID-19, patients presenting to NHS urology clinics will not be able to be prioritised with current tools. Arquer Diagnostics ha...

Every year 47,000 men are diagnosed with prostate cancer in the UK. Currently, diagnosis requires an invasive biopsy to be taken. This is painful for the patient, burdomesome to the NHS and carries the risk of infection requiring further treatment. Arquer have a simple test, optimised for bladder cancer, capable of detecting cancerous cells in urine. As p...

Bladder and prostate cancer are notoriously difficult to detect without invasive examination. The only reliable method for detecting bladder cancer is an expensive and intrusive visual examination of the inside of the bladder using an endoscope. The commonly used PSA test for prostate cancer produces around three ‘false positive’ readings for every correc...